Holen Sie sich die Stockscreener-App
23.15
4.10%
-0.99
Handel nachbörslich:
23.59
0.44
+1.90%
Schlusskurs vom Vortag:
$24.14
Offen:
$23.72
24-Stunden-Volumen:
1.46M
Relative Volume:
0.61
Marktkapitalisierung:
$2.92B
Einnahmen:
$715.22M
Nettoeinkommen (Verlust:
$-250.10M
KGV:
-11.40
EPS:
-2.03
Netto-Cashflow:
$-205.58M
1W Leistung:
-8.17%
1M Leistung:
-6.84%
6M Leistung:
+19.76%
1J Leistung:
-15.45%
1-Tages-Spanne:
$23.10
$23.93
1-Wochen-Bereich:
$23.10
$26.37
52-Wochen-Spanne:
$16.10
$35.72
Apellis Pharmaceuticals Inc Stock (APLS) Company Profile
Firmenname
Apellis Pharmaceuticals Inc
Sektor
Branche
Telefon
617-977-5700
Adresse
100 FIFTH AVENUE, WALTHAM, KY
Vergleichen Sie APLS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
APLS
Apellis Pharmaceuticals Inc
|
23.15 | 3.05B | 715.22M | -250.10M | -205.58M | -2.03 |
|
VRTX
Vertex Pharmaceuticals Inc
|
412.22 | 104.45B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
469.36 | 60.95B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
572.60 | 59.11B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
812.95 | 49.23B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.94 | 35.92B | 4.56B | -176.77M | 225.30M | -1.7177 |
Apellis Pharmaceuticals Inc Stock (APLS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-09-26 | Herabstufung | Goldman | Neutral → Sell |
| 2025-05-09 | Herabstufung | BofA Securities | Buy → Neutral |
| 2025-05-09 | Herabstufung | Raymond James | Strong Buy → Outperform |
| 2025-04-29 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-12-17 | Herabstufung | Goldman | Buy → Neutral |
| 2024-11-21 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2024-10-25 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2024-10-16 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-10-16 | Eingeleitet | William Blair | Outperform |
| 2024-05-31 | Eingeleitet | Piper Sandler | Neutral |
| 2024-02-05 | Hochstufung | Jefferies | Hold → Buy |
| 2023-12-14 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2023-11-09 | Eingeleitet | Goldman | Buy |
| 2023-11-02 | Eingeleitet | Mizuho | Neutral |
| 2023-10-06 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2023-09-15 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2023-08-29 | Bestätigt | Citigroup | Buy |
| 2023-08-03 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2023-08-01 | Herabstufung | BofA Securities | Buy → Neutral |
| 2023-01-03 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2022-11-10 | Herabstufung | Jefferies | Buy → Hold |
| 2022-07-19 | Eingeleitet | H.C. Wainwright | Buy |
| 2022-06-17 | Fortgesetzt | Stifel | Buy |
| 2022-04-14 | Herabstufung | ROTH Capital | Neutral → Sell |
| 2021-12-08 | Eingeleitet | Wells Fargo | Overweight |
| 2021-11-29 | Herabstufung | ROTH Capital | Buy → Neutral |
| 2021-09-10 | Bestätigt | BMO Capital Markets | Outperform |
| 2021-09-10 | Bestätigt | Credit Suisse | Neutral |
| 2021-09-10 | Bestätigt | Needham | Buy |
| 2021-09-10 | Bestätigt | Oppenheimer | Outperform |
| 2021-09-10 | Herabstufung | Wedbush | Outperform → Neutral |
| 2021-08-19 | Eingeleitet | Jefferies | Buy |
| 2021-08-19 | Hochstufung | Wedbush | Neutral → Outperform |
| 2021-05-21 | Eingeleitet | UBS | Buy |
| 2021-04-16 | Eingeleitet | Goldman | Buy |
| 2020-11-19 | Eingeleitet | Needham | Buy |
| 2020-09-01 | Eingeleitet | Stifel | Buy |
| 2020-07-20 | Eingeleitet | ROTH Capital | Buy |
| 2020-06-17 | Eingeleitet | BTIG Research | Neutral |
| 2020-04-01 | Eingeleitet | Raymond James | Strong Buy |
| 2020-03-31 | Eingeleitet | BMO Capital Markets | Outperform |
| 2020-03-11 | Hochstufung | Wedbush | Underperform → Neutral |
| 2020-01-07 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2019-12-19 | Eingeleitet | BofA/Merrill | Buy |
| 2019-11-22 | Eingeleitet | Wedbush | Underperform |
| 2019-11-05 | Eingeleitet | Credit Suisse | Neutral |
| 2019-08-01 | Bestätigt | Cantor Fitzgerald | Overweight |
| 2019-07-12 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2019-03-29 | Eingeleitet | Robert W. Baird | Outperform |
| 2019-01-23 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2018-07-30 | Hochstufung | B. Riley FBR | Neutral → Buy |
| 2018-05-24 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2018-04-12 | Herabstufung | B. Riley FBR, Inc. | Buy → Neutral |
| 2018-02-08 | Eingeleitet | B. Riley FBR, Inc. | Buy |
Alle ansehen
Apellis Pharmaceuticals Inc Aktie (APLS) Neueste Nachrichten
Apellis Pharmaceuticals Inc.’s volatility index tracking explained2025 Performance Recap & Free Expert Approved Momentum Trade Ideas - newser.com
Real time scanner hits for Apellis Pharmaceuticals Inc. explainedMarket Trend Report & Fast Momentum Stock Entry Tips - newser.com
Key resistance and support levels for Apellis Pharmaceuticals Inc.Earnings Recap Summary & Daily Profit Maximizing Trade Tips - newser.com
Can Apellis Pharmaceuticals Inc. stock surprise with earnings upsideTrade Performance Summary & Target Return Focused Stock Picks - newser.com
How sentiment analysis helps forecast Apellis Pharmaceuticals Inc.Weekly Investment Summary & AI Optimized Trading Strategy Guides - newser.com
How to integrate Apellis Pharmaceuticals Inc. into portfolio analysis tools2025 Market Trends & Verified Trade Idea Suggestions - newser.com
Applying chart zones and confluence areas to Apellis Pharmaceuticals Inc.Earnings Overview Report & Daily Technical Stock Forecast Reports - newser.com
What high frequency data says about Apellis Pharmaceuticals Inc.July 2025 Update & High Accuracy Trade Alerts - newser.com
How to forecast Apellis Pharmaceuticals Inc. trends using time seriesQuarterly Risk Review & Free Expert Verified Stock Movement Alerts - newser.com
Using R and stats models for Apellis Pharmaceuticals Inc. forecastingDividend Hike & Proven Capital Preservation Tips - newser.com
Eastern Bank Cuts Position in Apellis Pharmaceuticals, Inc. $APLS - MarketBeat
What analysts say about Apellis Pharmaceuticals Inc stockVWAP Trading Strategies & Master Stock Selection - earlytimes.in
Complement 3 Glomerulopathy Pipeline 2025: Therapies Under Investigation, Clinical Trials Milestones, and FDA Approvals by DelveInsight | ChemoCentryx, Novartis, Omeros Corporation, Apellis Pharma - Barchart.com
Price momentum metrics for Apellis Pharmaceuticals Inc. explainedQuarterly Trade Summary & Daily Technical Stock Forecast Reports - newser.com
Using Bollinger Bands to evaluate Apellis Pharmaceuticals Inc.Quarterly Portfolio Summary & Growth Oriented Trading Recommendations - newser.com
Identifying reversal signals in Apellis Pharmaceuticals Inc.2025 Performance Recap & AI Driven Stock Reports - newser.com
Fierce Biotech Layoff Tracker 2025: Ascidian Tx trims team; Ferring plots 500 layoffs - fiercebiotech.com
How to monitor Apellis Pharmaceuticals Inc. with trend dashboardsJuly 2025 Retail & Reliable Price Breakout Alerts - newser.com
Why retail investors pile into Apellis Pharmaceuticals Inc. stock2025 Support & Resistance & Momentum Based Trading Signals - newser.com
Weiss Ratings Reiterates Sell (E+) Rating for Apellis Pharmaceuticals (NASDAQ:APLS) - MarketBeat
Using data tools to time your Apellis Pharmaceuticals Inc. exitJuly 2025 Patterns & Real-Time Volume Trigger Notifications - newser.com
Piper Sandler Maintains Apellis Pharmaceuticals(APLS.US) With Hold Rating, Raises Target Price to $28 - 富途牛牛
Published on: 2025-10-05 07:38:09 - newser.com
Volume spikes in Apellis Pharmaceuticals Inc. stock – what they meanJuly 2025 Drop Watch & Fast Moving Trade Plans - newser.com
Can Apellis Pharmaceuticals Inc. (1JK) stock sustain institutional flows2025 Price Momentum & Smart Money Movement Tracker - newser.com
Smart tools for monitoring Apellis Pharmaceuticals Inc.’s price action2025 Market Outlook & Verified Swing Trading Watchlist - newser.com
Candlestick signals on Apellis Pharmaceuticals Inc. stock todayWeekly Trade Analysis & Accurate Buy Signal Alerts - newser.com
J. Safra Sarasin Holding AG Buys 68,588 Shares of Apellis Pharmaceuticals, Inc. $APLS - MarketBeat
Wall Street Has a Mixed Opinion on Apellis Pharmaceuticals (APLS) - MSN
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - 富途牛牛
What Fibonacci levels say about Apellis Pharmaceuticals Inc. reboundTrade Signal Summary & Entry Point Strategy Guides - newser.com
What MACD and RSI say about Apellis Pharmaceuticals Inc.2025 Institutional Moves & Long Hold Capital Preservation Plans - newser.com
HC Wainwright Brokers Lower Earnings Estimates for APLS - MarketBeat
Apellis Pharmaceuticals: Continued EMPAVELI Expansions Beyond PNH And C3G-Disorders - Seeking Alpha
Apellis Pharmaceuticals CFO Timothy Sullivan sells $51,827 in stock - MSN
Finanzdaten der Apellis Pharmaceuticals Inc-Aktie (APLS)
Umsatz
Nettogewinn
Free Cashflow
ENV
Apellis Pharmaceuticals Inc-Aktie (APLS) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Dunlop A. Sinclair | Director |
Sep 19 '25 |
Sale |
22.95 |
31,092 |
713,561 |
68,908 |
5.15%
1.45%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):